Motrem is under clinical development by Inotrem and currently in Phase II for Septic Shock. According to GlobalData, Phase II drugs for Septic Shock have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Motrem’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Motrem is under development for the treatment of septic shock, Coronavirus disease 2019 (COVID-19), atherosclerosis, myocardial infarction and polytrauma. The drug candidate is administered intravenously. The drug candidate is a 12 amino acid peptide fragment (LR12) derived from the protein TREM like Transcript-1 (TLT-1). It acts by targeting TREM-1.
Inotrem is a biopharmaceutical company that discovers and develops drugs for treating sepsis and septic shock. The company’s pipeline portfolio comprise of Phase I stage drugs Motorem is used for septic shock and CardioTerm which is used for acute myocardial infarction. Its TREM-1 pathway focuses on the development of immunomodulation targeting of the amplification loops in innate immune response for treating sepsis and septic shock. Inotrem’s research is focused on the development of immunotherapies for the treatment of inflammatory diseases. The company operates in France through its offices in Vandœuvre-les-Nancy and Paris. Inotrem is headquartered in Paris, Ile-de-France, France.
For a complete picture of Motrem’s drug-specific PTSR and LoA scores, buy the report here.